August 2012
-
GlaxoSmithKline and Theravance have submitted a marketing application to the EMA for their umeclidinium bromide (UMEC)/vilanterol (VI) dry powder inhaler for the treatment of COPD. The product, which is delivered using the Ellipta DPI, would… Read more . . .
-
Catalent Pharma Solutions has announced that it will invest $20 million to enhance pMDI clinical and commercial supply capabilities, along with other enhancements, at its Inhalation Center of Excellence in Research Triangle Park (RTP), North… Read more . . .
-
Lars Borgström Consulting has joined the Medicon Valley Inhalation Consortium (MVIC), bringing the group of companies involved in inhalation product development in the Skåne-Copenhagen region to 14 members. Borgström, the first recipient of RDD’s Charles… Read more . . .
-
The Bluetooth Special Interest Group (SIG) has named Asthmapolis a finalist in the “Breakthrough Products” category for the Bluetooth Breakthrough Awards. The FDA granted 510(k) clearance to the Asthmapolis inhaler sensor system and mobile app… Read more . . .
-
The Biomedical Catalyst, a joint program of the UK’s Medical Research Council and the Technology Strategy Board, has awarded a grant of up to £1.3M in matched funding to Prosonix for support of a research… Read more . . .
-
Discovery Laboratories has named John G. Cooper as President and CEO replacing W. Thomas Amick, who had been chairman of the board since March 2007 and CEO since October 2010. Cooper was Executive VP and… Read more . . .
-
Trimel Pharmaceuticals has named Tom Rossi as CEO to replace Bruce D. Brydon, who has stepped down as CEO. Rossi has been President of Trimel since he joined the company in August 2011 and also… Read more . . .
-
Teva Respiratory says that the ProAir HFA metered dose inhaler with dose counter for the treatment of asthma is now available. The albuterol MDI with dose counter was approved by the FDA in March 2012.… Read more . . .
-
The Carlyle group has agreed to sell Mitsubishi Chemical Holdings Corporation all outstanding shares of pharmaceutical capsule manufacturer Qualicaps. Products manufactured by Qualicaps include both gelatin and hypromellose capsules for use with dry powder inhalers.… Read more . . .
-
Alexza Pharmaceuticals has announced the appointment of J. Kevin Buchi to its board of directors. Buchi, who was Corporate Vice President, Global Branded Products at Teva Pharmaceutical Industries from October 2011 until May 2012, has… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland